HOME >> MEDICINE >> NEWS
Mouse shows how Rituximab removes human B cells

The monoclonal antibody Rituximab has been approved for the treatment of non-Hodgkin's lymphoma since 1997, but how Rituximab disposes of the cancerous (and normal) B cells is unknown. Research in a new mouse model reported in The Journal of Experimental Medicine suggests that the drug works by triggering the removal of B lymphocytes by scavenger cells.

Antibodies like Rituximab can remove cells in a variety of ways, including killing cells directly, inducing cell suicide, or triggering killing by other immune cells and molecules. Rituximab binds to CD20, a protein found on the surface of all B lymphocytes. In humans it is difficult to analyze how this leads to the elimination of B lymphocytes as only small numbers of cells can be sampled from the blood.

To mimic the clinical situation, Thomas Tedder and colleagues treated mice with a panel of antibodies specific for mouse CD20 (Rituximab is an antibody that binds to human but not mouse B cells). The antibodies that were effective in removing B cells did so by allowing B cell recognition by specialized 'scavenger' immune cells known as macrophages, which carry antibody receptors on their surface.

Less than half of patients with lymphoma respond to anti-CD20 therapy, so drugs that increase the number of macrophages or levels of antibody receptors might improve the response to Rituximab.

The new insight into how CD20 antibodies remove B cells should allow the design of better therapies not only for lymphoma, but also autoimmune diseases caused by rogue self-reactive B cells (as in rheumatoid arthritis), in which CD20 antibody trials are already underway.


'"/>

Contact: Nickey Henry
henryn@rockefeller.edu
212-327-8366
Journal of Experimental Medicine
21-Jun-2004


Page: 1

Related medicine news :

1. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
2. Mouse gene shows new mechanism behind cardiac infarction in man
3. Mouse model gives insight to human hair loss
4. Mouse study: Signal overload in Alzheimer brains
5. Mouse study could aid vaccine designers
6. Mouse model mimics real-world plague infection
7. Mouse antibodies thwart SARS virus
8. Mouse model of neuromuscular disease identifies key player in motor neuron death
9. Mouse study gives new view of anthrax toxin
10. Mouse studies reveal immune mechanism involved in bone loss caused by estrogen deficiency
11. Mouse provides clues about chronic pain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... September 26, 2017 , ... Ron Norman, CEO of ... use the Law of Large Numbers in favor of senior, upper-level executive job candidates ... casinos, have long understood the Law of Large Numbers as a way of protecting ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., an ... its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office is ... and Jon McCormack, both of whom have creative business development methods, who are responsive ...
(Date:9/26/2017)... Galloway, N.J. (PRWEB) , ... September 26, 2017 ... ... mocktail at the shore, the John R. Elliott HERO Campaign for Designated Drivers ... Hotel & Golf Club. , Thirty-one local bars and restaurants took on the ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Founded as ... decades growing into an innovative leader in special education. In 2018, Glenholme will ... , Glenholme, formerly a world renowned horse farm for Hackney show ponies, was generously ...
(Date:9/26/2017)... ... September 26, 2017 , ... The 2017 American Academy of Cosmetic Surgery ... Fat,” revealed not only the latest about cosmetic procedures to remove and replace fat, ... cosmetic medicine. , “Fat really is magical, especially when it comes to the cosmetic ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Sapheneia and Scannerside received FDA 510(k) clearance ... a third-party Vendor neutral CT product that makes it ... with current MITA standards. ... is specifically designed to provide CT operators, prior to ... over a predefined threshold. Scannerside Dose Check is intended ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a leading ... a vibrant charitable donation program -- "Color for ... congenital heart defect research by The Children,s Heart ... the general public are encouraged to download a ... the completed artwork to the gallery on the ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
Cached News: